ALTSGEYMER KASALLIGINI ERTA VA PREKLINIK DIAGNOSTIKA QILISHNING INNOVATSION YONDASHUVLARI: SUYUQLIK BIOMARKERLARI, NEYROIMAGING VA RAQAMLI TEXNOLOGIYALAR

Authors

DOI:

https://doi.org/10.5281/zenodo.23642772

Keywords:

Altsgeymer kasalligi, erta diagnostika, preklinik bosqich, biomarkerlar, amiloid-beta, fosforillangan tau, neyroimaging, magnit-rezonans tomografiya, pozitron-emission tomografiya, sun’iy intellekt, raqamli diagnostika

Abstract

Altsgeymer kasalligi demensiyaning eng keng tarqalgan sabablaridan biri bo‘lib, kognitiv funksiyalarning progressiv pasayishi va miya to‘qimalaridagi neyrodegenerativ o‘zgarishlar bilan tavsiflanadi. Kasallikni erta aniqlash, klinik simptomlar yaqqol namoyon bo‘lishidan oldin biologik jarayonlarni baholash va individual prognozni aniqlashtirish zamonaviy nevrologiyaning muhim vazifalaridan hisoblanadi. Maqolada Altsgeymer kasalligini erta va preklinik bosqichlarda aniqlashga qaratilgan zamonaviy diagnostik yondashuvlar ilmiy adabiyotlar asosida tahlil qilinadi. Qon plazmasi va orqa miya suyuqligidagi amiloid-beta, fosforillangan tau oqsillari, neyrofilament yengil zanjiri hamda glial fibrillyar kislotali oqsil kabi biomarkerlarning diagnostik imkoniyatlari yoritiladi. Shuningdek, magnit-rezonans tomografiya, amiloid va tau pozitron-emission tomografiyasi hamda sun’iy intellektga asoslangan raqamli diagnostika texnologiyalarining o‘rni ko‘rib chiqiladi. Tahlil natijalari turli diagnostik usullarni kompleks qo‘llash kasallik bilan bog‘liq biologik o‘zgarishlarni aniqlash imkoniyatlarini kengaytirishi mumkinligini ko‘rsatadi. Biroq ularni klinik amaliyotga joriy etishda diagnostik aniqlik, iqtisodiy samaradorlik, mavjud cheklovlar va etik talablarni hisobga olish zarur.

References

1. Jack, C. R. Jr., Andrews, J. S., Beach, T. G., et al. (2024). Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia, 20(8), 5143–5169.

2. Palmqvist, S., Whitson, H. E., Allen, L. A., et al. (2025). Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alzheimer’s & Dementia. 2025;21(7). https://doi.org/10.1002/alz.70535. https://doi.org/10.1002/alz.70535

3. Mielke, M. M., & Fowler, N. R. (2024). Alzheimer disease blood biomarkers: considerations for population-level use. Nature Reviews Neurology, 20, 495–504. https://doi.org/10.1038/s41582-024-00989-1

4. Rabinovici, G. D., Knopman, D. S., Arbizu, J., et al. (2025). Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimer’s & Dementia. 2025;21(1). https://doi.org/10.1002/alz.14338. https://doi.org/10.1002/alz.14338

5. Jack, C. R. Jr., Bennett, D. A., Blennow, K., et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562. https://doi.org/10.1016/j

6. Hansson, O. (2021). Biomarkers for neurodegenerative diseases. Nature Medicine, 27, 954–963.

Downloads

Published

2026-10-20

How to Cite

1.
Amirova MT qizi, Butunboyeva MQ qizi, Shevketova DI, Musurmonova BK, Sharipova DM qizi. ALTSGEYMER KASALLIGINI ERTA VA PREKLINIK DIAGNOSTIKA QILISHNING INNOVATSION YONDASHUVLARI: SUYUQLIK BIOMARKERLARI, NEYROIMAGING VA RAQAMLI TEXNOLOGIYALAR. TTI [Internet]. 2026 Oct. 20 [cited 2026 Nov. 19];2(10):450-5. Available from: https://tibbiyot-talimi-va-innovatsiyalari.uz/index.php/TTI/article/view/189
Vol. 2 No. 10 (2026): Journal of "Medical Education and Innovations"